The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature
The DOI matches its Crossref record; 250 of the 251 references it cites were found in a registry or an index.
Abstract
Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later. They encompass gastrointestinal symptoms (nausea, diarrhea, gastric bleeding, dyspepsia), hepatotoxicity, weight gain and metabolic abnormalities, cardiovascular disturbances (heart rate, QT interval prolongation, hypertension, orthostatic hypotension), genitourinary symptoms (urinary retention, incontinence), sexual dysfunction, hyponatremia, osteoporosis and risk of fractures, bleeding, central nervous system disturbances (lowering of seizure threshold, extrapyramidal side effects, cognitive disturbances), sweating, sleep disturbances, affective disturbances (apathy, switches, paradoxical effects), ophthalmic manifestations (glaucoma, cataract) and hyperprolactinemia. At times, such adverse events may persist after drug discontinuation, yielding iatrogenic comorbidity. Other areas of concern involve suicidality, safety in overdose, discontinuation syndromes, risks during pregnancy and breast feeding, as well as risk of malignancies. Thus, the rational selection of ADs should consider the potential benefits and risks, likelihood of responsiveness to the treatment option and vulnerability to adverse events. The findings of this review should alert the physician to carefully review the appropriateness of AD prescription on an individual basis and to consider alternative treatments if available.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Common side effects include nausea, vomiting, diarrhea, headache, insomnia, and agitation (104).”
From The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease (2023) · cites this paper as [104]
In the citing paper
“Another drawback of long-term antidepressant treatment is concerned with the serious and bothersome side effects that may ensue with SSRI and SNRI, such as high rates of sexual dysfunction, bleeding (in particular gastrointestinal), weight gain, risk of fracture and osteoporosis, and hyponatremia.73”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [73]
In the citing paper
“Examples are switching from unipolar to bipolar course with antidepressant drugs [6,31] and supersensitivity psychosis, the onset of psychotic symptoms and co-occurring movement disorder with antipsychotic medications [4].”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [6]
In the citing paper
“For instance, several side effects of antidepressants are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later.”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [6]
In the citing paper
“Since gastric symptomatology did not follow the somatic patterns typical of anxiety disturbances, venlafaxine was also suspected as a iatrogenic cause [6].”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Items 201–250 of 250
Boucher, N., Koren, G., & Beaulac-Baillargeon, L. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181a58fb4 · Cited by 42
Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy
Fava, G. A., Tomba, E., & Tossani, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.014 · Cited by 41
Self-citationPsychotropics and sexual dysfunction
Bell, A., & Shamloul, R. M. (2013) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2013.04.art22 · Cited by 40
Duhoux, A., Fournier, L., Gauvin, L. I., & Roberge, P. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.097 · Cited by 39
Use of antidepressants and the risk of breast cancer: a meta-analysis
Eom, C.-S., Park, S. M., & Cho, K.-H. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2307-y · Cited by 38
Rosenblat, J. D., Gregory, J. M., Carvalho, A. F., & McIntyre, R. S. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160126144303 · Cited by 38
Self-citationPatients’ attitudes toward side effects of antidepressants: an Internet survey
Kikuchi, T., Uchida, H., Suzuki, T., Watanabe, K., & Kashima, H. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0124-z · Cited by 37
Risk of Angle-Closure Glaucoma With Bupropion and Topiramate
Symes, R. J., Etminan, M., & Mikelberg, F. S. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.2180 · Cited by 37
Venlafaxine and bilateral acute angle closure glaucoma
Ng, B., Sanbrook, G. M. C., Malouf, A. J., & Agarwal, S. A. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04386.x · Cited by 37
An Overview of Vortioxetine: (Academic Highlights)
Schatzberg, A. F., Blier, P., Culpepper, L., Jain, R., Papakostas, G. I., & Thase, M. E. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14027ah1 · Cited by 36
Risk of Suicidal Behavior With Antidepressants in Bipolar and Unipolar Disorders
Leon, A. C., Fiedorowicz, J. G., Solomon, D. A., Li, C., Coryell, W. H., Endicott, J., Fawcett, J., & Keller, M. B. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08744 · Cited by 36
Erie, J. C., Brue, S. M., Chamberlain, A. M., & Hodge, D. O. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.03.006 · Cited by 36
Duloxetine in the treatment of major depressive disorder
GOLDSTEIN, D. J. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.193 · Cited by 36
Bupropion in the Depression-Related Sexual Dysfunction: A Systematic Review
Pereira, V., Arias-Carrion, O., Machado, S., Nardi, A., & Silva, A. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612112630 · Cited by 36
Brandao, D. F., Strasser-Weippl, K., & Goss, P. (2016) · Cancer · doi:10.1002/cncr.29714 · Cited by 35
Cyproheptadine for Drug-Induced Sweating
Ashton, A. K., & Weinstein, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.874-a · Cited by 35
DeVane, C. L. (2003) · PubMed · Cited by 33
Barbui, C., Hotopf, M. H., Freemantle, N., Boynton, J. R., Churchill, R. C., Eccles, M. P., Geddes, Hardy, R., Lewis, G., & Mason, J. M. (2006) · UCL Discovery (University College London) · Cited by 32
Castro-Rodríguez, J. I., Olariu, E., Garnier, C., Martín‐Lopez, L. M., Pérez, V., Alonso, J., & Forero, C. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.020 · Cited by 31
Simultaneous bilateral acute angle closure glaucoma following venlafaxine treatment
Ezra, D. G., Storoni, M., & Whitefield, L. A. (2005) · Eye · doi:10.1038/sj.eye.6701815 · Cited by 31
Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults
Bhattacharya, R., Ajmera, M., Bhattacharjee, S., & Sambamoorthi, U. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.016 · Cited by 28
AHL, J. S. B., Perahia, Bangs, M. E., Zhang, Cheng, Y., Frakes, E. P., Adams, M. L., & Martinez, J. M. (2013) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s45445 · Cited by 28
Szmulewicz, A., Samamé, C., Caravotta, P., Martino, D. J., Igoa, A., Hidalgo-Mazzei, D., Colom, F., & Strejilevich, S. A. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0047-3 · Cited by 28
Long-Term Use of Selective Serotonin Reuptake Inhibitors and Risk of Glaucoma in Depression Patients
Chen, H., Lin, C., & Kao, C. (2015) · Medicine · doi:10.1097/md.0000000000002041 · Cited by 28
Serotonin Reuptake Inhibitors and Hyperprolactinaemia
Trenque, T. C., Herlem, E., Auriche, P., & Dramé, M. (2011) · Drug Safety · doi:10.2165/11595660-000000000-00000 · Cited by 27
Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs)
Hedenmalm, K., Sundström, A., & Spigset, O. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1270 · Cited by 26
Mondal, S., Saha, I., Das, S., Ganguly, A., Das, D., & Tripathi, S. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313490305 · Cited by 25
Stubbs, B., Brefka, S., Dallmeier, D., Stubbs, J., Vancampfort, D., & Denkinger, M. D. (2016) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000292 · Cited by 25
The influence of citalopram on interdigestive gastrointestinal motility in man
Janssen, P., Vos, R., & Tack, J. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04351.x · Cited by 22
Cusin, C., Fava, M., Amsterdam, J. D., Quitkin, F. M., Reimherr, F. W., Beasley, C. M., Rosenbaum, J. F., & Perlis, R. H. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0107 · Cited by 22
Silva, M. A. D., Dugravot, A., Balkau, B., Roussel, R., Fumeron, F., Elbaz, A., Canonico, M., Singh‐Manoux, A., Nabi, H., & the D.E.S.I.R. Study Group (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv153 · Cited by 22
Harvey, A. T., Silkey, B. S., Kornstein, S. G., & Clary, C. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0620 · Cited by 21
Nußbaumer-Streit, B., Morgan, L. C., Reichenpfader, U., Greenblatt, A. M., Hansen, R. A., Noord, M. V., Lux, L. J., Gaynes, B. N., & Gartlehner, G. (2014) · CNS Drugs · doi:10.1007/s40263-014-0169-z · Cited by 18
Mahasuar, R., Majhi, P., & Ravan, J. R. (2009) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.07.006 · Cited by 18
Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
Yu, S., Zhang, X., Wu, L., Wan, D., Liu, R., Dong, Z., & Chen, M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s87968 · Cited by 17
Newer antidepressants for the treatment of depression in adults
Hatcher, S., & Arroll, B. (2012) · BMJ · doi:10.1136/bmj.d8300 · Cited by 17
Starčević, V., Brakoulias, V., Viswasam, K., & Berle, D. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000439137 · Cited by 15
Nassir Ghaemi, S., Vohringer, P. A., & Whitham, E. A. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12059 · Cited by 15
N. Fountoulakis, K., S. McIntyre, R., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630174343 · Cited by 15
Self-citationMengensatzproduktion, S., Stückle, D., & Stückle, D. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000438780 · Cited by 13
Putative Neuroleptic Malignant Syndrome Associated With Sertraline Withdrawal
Konstantakopoulos, G., Kouzoupis, A. V., Papageorgiou, S. G., & Oulis, P. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a39101 · Cited by 11
Antidepressants and, suicide and self-injury: Causal or casual association?
Pozzi, M., Radice, S., Clementi, E., Molteni, M., & Nobile, M. (2016) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2015.1117111 · Cited by 11
Elevated Rest Heart Rate in Psychiatric Patients and Different Effects of Psychotropic Medication
Sarlon, J., Habich, O., & Schneider, B. (2015) · Pharmacopsychiatry · doi:10.1055/s-0035-1565204 · Cited by 11
Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Europe PMC (PubMed Central) · Cited by 10
Euprolactinemic Galactorrhea With Escitalopram
Praharaj, S. K. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13070147 · Cited by 10
Brvar, M., Štajer, D., Koželj, G., Osredkar, J., Možina, M., & Bunc, M. (2007) · Clinical Toxicology · doi:10.1080/15563650601118101 · Cited by 9
Morriss, R. K. (2016) · Evidence-Based Mental Health · doi:10.1136/eb-2015-102212 · Cited by 8
Prescriber's Guide to Using 3 New Antidepressants: Vilazodone, Levomilnacipran, Vortioxetine
Elmaadawi, A. Z., Singh, N., Reddy, J., & Nasr, S. J. (2015) · Current psychiatry · Cited by 7
Iatrogenic comorbidity in mental health
Fava, G. A., Cosci, F., & Tomba, E. (2015) · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) · Cited by 6
Self-citationAssociation between antidepressants and breast/ovarian cancer
Pae, C. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.647684 · Cited by 1
Research works printed but not linked: 1
- 10.1345/aph.1A254 · doi:10.1345/aph.1a254 · Paper page
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Self-citationMcCarron, R. M., Shapiro, B., Rawles, J., & Luo, J. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202105180 · Cited by 492
Buckman, J. E. J., Underwood, A., Clarke, K., Saunders, R., Hollon, S. D., Fearon, P., & Pilling, S. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.07.005 · Cited by 398
Depression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 375
Self-citationKietaibl, S., Ahmed, A., Afshari, A., Albaladejo, P., Aldecoa, C., Barauskas, G., De Robertis, E., Faraoni, D., Filipescu, D. C., Fries, D., et al. (2023) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001803 · Cited by 345
Metadata
- Authors
- Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Universidade de São Paulo (BR)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- University at Buffalo, State University of New York (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 85
- Issue
- 5
- Pages
- 270-288
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2477696699
- Semantic Scholar
- 4af046d5cf1f48ed09514ffef416d2de5c0d29cf
- Cited by
- 650
- References
- 251
- Citations by year
- 2026: 46 · 2025: 67 · 2024: 95 · 2023: 84 · 2022: 81 · 2021: 75 · 2020: 55 · 2019: 54 · 2018: 50 · 2017: 38 · 2016: 4
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- newer antidepressants, antidepressant side effects, drug safety, tolerability, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran, vortioxetine, gastrointestinal adverse effects, hepatotoxicity, weight gain, QT prolongation, sexual dysfunction, hyponatremia, osteoporosis, paradoxical effects, suicidality, antidepressant overdose, discontinuation syndrome, pregnancy and lactation, cancer risk, drug selection
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.